Stent News: Breaking Stent News, Comments and Articles. - Page: 3

Biosensors Reports Financial Results for Fiscal Year 2013

SINGAPORE, May 29, 2013 /PRNewswire/ -- Biosensors International Group, Ltd. ("Biosensors" or the "Company", Bloomberg: BIG SP; Reuters: BIOS.SI; SGX: B20), a developer, manufacturer and marketer of innovative medical devices, today announced financial results for its fourth fiscal quarter (Q4 FY13) and fiscal full year ended 31 March 2013 (FY13). Highlights and Other Recent Update...

OrbusNeich introduces COMBO Dual Therapy Stent

OrbusNeich today launched the world's first dual therapy stent – the COMBO Dual Therapy Stent – to address the challenges of delayed healing of the coronary artery associated with monotherapy drug eluting stents, the current standard of care for...

OrbusNeich Launches World's First Dual Therapy Stent That Addresses Challenges of Delayed Coronary Artery Healing Associated with Monotherapy Drug Eluting Stents

HONG KONG, May 27, 2013 /PRNewswire/ -- OrbusNeich today launched the world's first dual therapy stent – the COMBO Dual Therapy Stent – to address the challenges of delayed healing of the coronary artery associated with monotherapy drug eluting stents (DES), the current standard of care for the treatment of coronary artery disease (CAD). The introduction of the COMBO Stent is in conjun...

Elixir Medical announces two-year results from EXCELLA BD randomized clinical trial

US-based medical devices developer Elixir Medical has announced that the results of its CE Mark-approved DESyne BD Novolimus Eluting Coronary Stent System with biodegradable polymer coating were outstanding.

Balloon Proves Mettle for Stent Restenosis (CME/CE)

PARIS (MedPage Today) -- A paclitaxel-eluting balloon worked just as well as a paclitaxel-eluting stent for treating drug-eluting stent restenosis, a Chinese trial showed.

Biosensors Completes Spectrum Dynamics Assets Acquisition

SINGAPORE, May 26, 2013 /PRNewswire/ --  Biosensors International Group, Ltd. ("Biosensors" or the "Company", Bloomberg: BIG SP; Reuters: BIOS.SI; SGX: B20), a developer, manufacturer and marketer of innovative medical devices, today announced the completion of its acquisition of substantially all assets of Spectrum Dynamics, a leader in advanced functional assessment technologies, including...

Zilver Stent Recalled, System May Break

(MedPage Today) -- Cook Medical's Zilver PTX drug-eluting stent for peripheral artery disease has been recalled because of a defect in its associated delivery system, the company and the FDA said.

Elixir Medical Corporation Announces Outstanding Two-Year Results from the EXCELLA BD Randomized Clinical Trial for the CE Mark-Approved DESyne® BD System with Biodegradable Polymer Coating

Results Set a High Standard in Sustained Long Term Clinical Outcomes Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced today excellent long-term results of its CE Mark-approved DESyne® BD Novolimus Eluting Coronary Stent System with biodegradable polymer coating c...

Orsiro Stent as Good as Xience Prime (CME/CE)

PARIS (MedPage Today) -- The sirolimus-eluting Orsiro stent with a biodegradable polymer coating performed comparably to the everolimus-eluting Xience Prime stent with a durable coating in patients with de novo coronary lesions, a randomized trial sh...

InspireMD To Participate In Benchmark Investor Conference On May 30th

BOSTON and TEL AVIV, Israel, May 24, 2013 /PRNewswire/ -- InspireMD, Inc. ("InspireMD" or the "Company") (NYSE MKT: NSPR), a leader in embolic protection stents, announced that Alan Milinazzo, the Company's President and Chief Executive Officer, and Craig Shore, the Company's Chief Financial Officer, will participate in the Benchmark Company, LLC One-on-One Investor Conference on Thursday May 30,...

FDA to have stringent rules for medical apps

US Food and Drug Administration intends to have tighter rules for apps that allow diagnose or treat medical conditions, similar to the 2011 proposal urging for quality standards for ultrasound machines, heart stents, and several other medical equipme...

FDA plans to have stringent rules for medical apps

US Food and Drug Administration intends to have tighter rules for apps that allow to diagnose or treat medical conditions, similar to the 2011 proposal urging for quality standards for ultrasound machines, heart stents, and several other medical equi...

Results Of The BIOFLOW-II Substudy: Biodegradable Stent Proves Non-Inferior To Drug-Eluting Stent

The Orsiro stent, which is a novel stent platform eluting sirolimus from a biodegradable polymer, demonstrated non-inferiority to the Xience Prime everolimus-eluting stent for the primary angiographic endpoint of in-stent late lumen loss at nine mont...

Tryton Medical Announces Nordic-Baltic Dedicated Bifurcation Trial Studying the Tryton Side Branch Stent

Tryton Medical, Inc., the leading developer of stents designed to treat bifurcation lesions, today announced that the Nordic-Baltic Bifurcation Study Group will investigate the Tryton Side Branch Stent. The trial is a prospective, controlled, randomized, multicenter clinical study examining the role of final kissing balloon inflations in patient outcomes....

Cardiovascular Systems Presents New Late-Breaking Coronary Results at EuroPCR Conference

ORBIT II trial met primary endpoints treating patient population in which 99.3% of subjects had severely calcified lesions 30-day freedom from MACE rate of 89.8 percent Procedural success of 89.1 percent (including in-hospital MACE) New data shows:...

Svelte Drug-Eluting Stent Utilizing New Class of Bioabsorbable Drug Coating Attains 0% Clinically-Driven Events Through 12-Months in First-In-Man Study

Final 6 and 12-month results of the DIRECT first-in-man clinical study were presented by study principal investigator Dr. Mark Webster at the late-breaking clinical trials session of the EuroPCR meeting yesterday in Paris, France. No patients experienced clinically-driven TLR, TVR or MACE at 6-months, with results sustained through 12-months. It is believe...

Rectal Indomethacin and Pancreatic Stents in High-Risk ERCP

Do patients undergoing high-risk ERCP benefit from rectal indomethacin, or are prophylactic pancreatic stents still considered necessary? The American Journal of Gastroenterology

Axxess™ Self-Expanding Bifurcation Drug-Eluting Stent Shown to be Safe and Effective up to Four Years

Paris, France, 18 May 2012 – New long-term data from the DIVERGE study, presented yesterday at EuroPCR 2012 by Dr. John Ormiston, showed that the use of the Axxess™ drug-eluting stent (DES) for the treatment of complex coronary bifurcation lesions resulted in low levels of both MACE and VLST over a four-year period. Axxess™ is a self-expanding bifurcation stent which release...

Medtronic's In.Pact Falcon Drug-Eluting Balloon Yields Positive Outcomes in Small Coronary Arteries

Presented at EuroPCR, One-Year Data from BELLO Study Show Durability of Clinical Results Following Treatment of De Novo Lesions with Novel Angioplasty Device PARIS -- May 23, 2013 -- One-year data from an Italian multicenter randomized controlled trial of the IN.PACT Falcon drug-eluting balloon from Medtronic, Inc. (NYSE: MDT) demonstrate positive and durable clinical results with the novel ang...

InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group

PARIS, May 23, 2013 /PRNewswire/ -- InspireMD, Inc. ("InspireMD" or the "Company") (NYSE MKT: NSPR), the leader in embolic protection stents, today announced new 6-month results from the MASTER (MGuard for Acute ST Elevation Reperfusion) trial demonstrating that the MGuard Embolic Protection Stent (EPS) outperformed bare metal and drug eluting stents in all-cause mortality in ST segment elevation...

Volcano Announces Preliminary Results from the ADVISE II Study and Inclusion in the SYNTAX2 Trial During Hot Line Late Breaking Clinical Trial Sessions at EuroPCR 2013

SAN DIEGO and PARIS, May 23, 2013 /PRNewswire/ -- Volcano Corporation (NASDAQ: VOLC), a leading developer and manufacturer of precision guided therapy tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, today announced preliminary results from the ADVISE (Adenosine Vasodilator Independent Stenosis Evaluation) II trial during the hot line late bre...

Computational Model Evaluates A New Way To Open Clogged Arteries

Over the past few decades, scientists have developed many devices that can reopen clogged arteries, including angioplasty balloons and metallic stents. While generally effective, each of these treatments has drawbacks, including the risk of side effe...

Further Data on STENTYS Self-Apposing Stent Reinforces Strength of Clinical Results

New Sub-group Analysis of APPOSITION III Presented at EuroPCR in Paris STENTYS (FR0010949404 – STNT), a medical technology company commercializing in Europe the world's first and only Self-Apposing® Stent to treat acute myocardial infarction (AMI), announced today new one-year data from the APPOSITI

Direct Flow Medical Transcatheter Aortic Valve System Demonstrates Excellent 30 Day Outcomes Following Full Enrollment of DISCOVER CE Mark Trial

Results Presented in Oral Presentation at EuroPCR Direct Flow Medical®, Inc., a transcatheter heart valve company focused on improving patient outcomes, today announced that it has met its primary endpoint in the fully-enrolled, 100-patient DISCOVER CE Mark Trial by achieving 99 percent freedom from all-cause mortality at 30 days. Patients were...

Boston Scientific Promus PREMIER™ And SYNERGY™ Drug-Eluting Stent Systems Provide Exceptional Safety And Efficacy Data

PARIS, May 22, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) reports positive results from two trials evaluating new, innovative drug-eluting stent (DES) technologies, which are emerging treatment options for coronary heart disease.  Data from the first human use NG PROMUS Clinical Trial evaluating the safety and effectiveness of the Promus PREMIER™ Everolimus-Elut...